Perth, Feb 13, 2017 AEST (ABN Newswire) – MMJ PhytoTech Limited (ASX:MMJ) (“MMJ” or “the Company”) is pleased to advise that its wholly-owned, Israeli-based subsidiary PhytoTech Therapeutics Limited (“PTL”), has commenced following Health Authorities’ approval, the Phase 2 clinical study into the safety and efficacy of its PTL101 capsules in treating refractory epilepsy in children.
– Phase 2 clinical trial of PTL101, MMJ’s investigational drug, now underway, following completion of successful Phase 1 trial in 2016
– Phase 2 clinical trial is aimed at measuring safety and efficacy of the PTL101 drug-beads for reducing seizures frequency in children with refractory epilepsy
– Successful Phase 2 clinical trial will be a major step towards commercial development of the PTL101 drug for epilepsy treatment
– Preparation for an additional Phase 2 study to treat spasticity related